NO971403L - Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS - Google Patents

Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS

Info

Publication number
NO971403L
NO971403L NO971403A NO971403A NO971403L NO 971403 L NO971403 L NO 971403L NO 971403 A NO971403 A NO 971403A NO 971403 A NO971403 A NO 971403A NO 971403 L NO971403 L NO 971403L
Authority
NO
Norway
Prior art keywords
treatment
irds
ards
glucocorticoid
combination
Prior art date
Application number
NO971403A
Other languages
English (en)
Other versions
NO313405B1 (no
NO971403D0 (no
Inventor
Dietrich Haefner
Paul-Georg Germann
Klaus Eistetter
Ulrich Kilian
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO971403D0 publication Critical patent/NO971403D0/no
Publication of NO971403L publication Critical patent/NO971403L/no
Publication of NO313405B1 publication Critical patent/NO313405B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Steroid Compounds (AREA)
NO19971403A 1994-09-28 1997-03-25 Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS NO313405B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4434629A DE4434629C1 (de) 1994-09-28 1994-09-28 Zusammensetzungen zur Behandlung von IRDS und ARDS
PCT/EP1995/003816 WO1996009831A2 (de) 1994-09-28 1995-09-27 Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten

Publications (3)

Publication Number Publication Date
NO971403D0 NO971403D0 (no) 1997-03-25
NO971403L true NO971403L (no) 1997-04-17
NO313405B1 NO313405B1 (no) 2002-09-30

Family

ID=6529394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971403A NO313405B1 (no) 1994-09-28 1997-03-25 Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS

Country Status (25)

Country Link
US (1) US5891844A (no)
EP (1) EP0783314B1 (no)
JP (1) JP4425991B2 (no)
KR (1) KR100365030B1 (no)
CN (1) CN1100542C (no)
AT (1) ATE241372T1 (no)
AU (1) AU705099B2 (no)
BG (1) BG62556B1 (no)
CA (1) CA2201377C (no)
CZ (1) CZ292846B6 (no)
DE (2) DE4434629C1 (no)
DK (1) DK0783314T3 (no)
EE (1) EE03422B1 (no)
ES (1) ES2201120T3 (no)
FI (1) FI118886B (no)
HU (1) HU226958B1 (no)
MX (1) MX9702303A (no)
NO (1) NO313405B1 (no)
NZ (1) NZ294587A (no)
PL (1) PL187496B1 (no)
PT (1) PT783314E (no)
RU (1) RU2157222C2 (no)
SK (1) SK284446B6 (no)
UA (1) UA43378C2 (no)
WO (1) WO1996009831A2 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
JP2003501481A (ja) * 1999-06-11 2003-01-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング サーファクタントタンパク質ｂ（ｓｐ−ｂ）改変体およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）改変体を含有する医薬品製剤
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
AU2001265876A1 (en) * 2000-04-12 2001-10-23 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) * 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
RU2191031C2 (ru) * 2001-01-10 2002-10-20 Московский НИИ педиатрии и детской хирургии Способ лечения пневмоний у глубоконедоношенных детей, находящихся на искусственной вентиляции легких
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
US6998384B2 (en) * 2001-12-12 2006-02-14 The Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004110450A1 (en) 2003-06-16 2004-12-23 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
EP2298349A1 (en) 2005-01-06 2011-03-23 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
KR100891595B1 (ko) * 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
WO2008036293A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
EP2022798A1 (en) * 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2012077127A1 (en) * 2010-12-10 2012-06-14 Indian Institute Of Technology, Bombay A protein free surfactant composition for pulmonary diseases and a process for preparing the same
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
BR112019012922A2 (pt) * 2016-12-22 2019-12-10 Chiesi Farm Spa combinação de um surfactante pulmonar, uso de uma combinação de um surfactante pulmonar e kit
JP7378425B2 (ja) 2018-04-23 2023-11-13 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 肺サーファクタントおよびｂｐｄの予防のためのステロイドを含む治療的組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000868A1 (en) * 1986-08-08 1988-02-11 Kurzinski Cass R Apparatus and method for continuously casting steel slabs
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
RU2039560C1 (ru) * 1988-04-18 1995-07-20 Центр по химии лекарственных средств ВНИИХФИ Вещество, обладающее противоопухолевой активностью
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
FI971277L (fi) 1997-05-27
ATE241372T1 (de) 2003-06-15
DE59510705D1 (de) 2003-07-03
SK40197A3 (en) 1998-02-04
PL319608A1 (en) 1997-08-18
JP4425991B2 (ja) 2010-03-03
US5891844A (en) 1999-04-06
WO1996009831A2 (de) 1996-04-04
EE9700084A (et) 1997-10-15
JPH10506119A (ja) 1998-06-16
CZ94097A3 (en) 1997-09-17
EP0783314B1 (de) 2003-05-28
HU226958B1 (en) 2010-03-29
EE03422B1 (et) 2001-06-15
DE4434629C1 (de) 1996-06-27
PT783314E (pt) 2003-10-31
BG62556B1 (bg) 2000-02-29
CZ292846B6 (cs) 2003-12-17
EP0783314A2 (de) 1997-07-16
BG101441A (en) 1997-09-30
CN1100542C (zh) 2003-02-05
NO313405B1 (no) 2002-09-30
WO1996009831A3 (de) 1996-05-23
CA2201377A1 (en) 1996-04-04
AU705099B2 (en) 1999-05-13
NZ294587A (en) 1998-07-28
NO971403D0 (no) 1997-03-25
FI118886B (fi) 2008-04-30
ES2201120T3 (es) 2004-03-16
AU3742895A (en) 1996-04-19
PL187496B1 (pl) 2004-07-30
MX9702303A (es) 1997-06-28
SK284446B6 (sk) 2005-04-01
HK1003869A1 (en) 1998-11-13
KR100365030B1 (ko) 2003-03-10
RU2157222C2 (ru) 2000-10-10
CA2201377C (en) 2008-07-29
CN1163571A (zh) 1997-10-29
DK0783314T3 (da) 2003-12-01
FI971277A0 (fi) 1997-03-26
KR970706006A (ko) 1997-11-03
UA43378C2 (uk) 2001-12-17
HUT77931A (hu) 1998-11-30

Similar Documents

Publication Publication Date Title
NO971403D0 (no) Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS
DE3586959D1 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
PH19733A (en) Aromatic heterocyclic esters of steroids,pharmaceutical compositions containing them and their use
NO161129C (no) Fremgangsmaate for inklusjon av mikroorganismer fra gruppen av mycorrhizae og actinorrhizae i en polymergelmatriks.
EP0357675A4 (en) Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
DK40986A (da) 4h-1-benzopyran-4-oner og deres svovlholdige analoge, og farmaceutiske kompositioner indeholdende forbindelserne
ATE164159T1 (de) Substituierte triole
EP0751954A4 (en) ANTI-INFLAMMATORY COMPOSITION AND METHOD IN WHICH DES-TYR DYNORPHINE AND THE LIKE ARE USED
DE3264461D1 (en) 1-dodecylazacycloheptan-2-one used in anti-inflammatory compositions
DK0665716T3 (da) Bagesammensætning med højt sukkerindhold
DE3575288D1 (de) Feuerfeste zusammensetzung und daraus hergestellte koerper.
MY107976A (en) Improvements in or relating to organic compounds
GR3019121T3 (en) Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
DK399985A (da) 6-substituerede mitomycin-analoge, deres anvendelse inden for medicinen og kompositioner indeholdende forbindelserne
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.
NO156851C (no) Innretning for videretransport av reker i innrettet og ordnet tilstand.
DE3764014D1 (de) Mit substituierten aminocarbamaten stabilisierte zusammensetzungen und neue substituierte aminocarbamate.
FR2543415B1 (fr) Perfectionnements apportes aux pietements pivotants, et mobilier, notamment elements de barriere deplacable, equipe de tels pietements
DE3486407D1 (de) Zusammensetzung zur Kontrolle der Hämophilie bei Säugetieren.
DE69322629D1 (de) Selbstkonvergierende und in der geometrie korrigierte elektronenablenkeinheit für kathodenstrahlröhren
DK330687A (da) Forbindelser og farmaceutiske kompositioner, der er anvendelige som cardiotoniske midler
EP0468327A3 (en) Oral pharmaceutical compositions containing hirudin
FR2543416B1 (fr) Perfectionnements apportes aux pietements pivotants, et mobilier, notamment elements de barriere deplacable, equipe de tels pietements
DK199983D0 (da) Analoge til neurohypofysiske hormoner med haemmende egenskaber

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

MM1K Lapsed by not paying the annual fees